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Abstract
Background: Current research has established obesity as one of the main modifiable risk factors for cognitive
impairment. However, evidence on the relationships of total and regional body composition measures as well as
sarcopenia with cognitive functioning in the older population remains inconsistent.
Methods: Data are based on 1,570 participants from the British Regional Heart Study (BRHS), a cohort of older
British men from 24 British towns initiated in 1978–80, who were re-examined in 2010–12, aged 71–92 years.
Cognitive functioning was assessed with the Test-Your-Memory cognitive screening tool. Body composition
characteristics assessed using bioelectrical impedance analysis included total fat mass (FM), central FM, peripheral
FM, and visceral fat level. Sarcopenia was defined using the European Working Group on Sarcopenia in Older
People (EWGSOP) definition of severe sarcopenia and the Foundation for the National Institutes of Health (FNIH)
sarcopenia project criteria.
Results: Among 1,570 men, 636 (41 %) were classified in the mild cognitive impairment (MCI) and 133 (8 %) in the
severe cognitive impairment (SCI) groups. Age-adjusted multinomial logistic regressions showed that compared
with participants in the normal cognitive ageing group, those with SCI were more likely to have waist
circumference >102 cm, BMI >30 kg/m2, to be in the upper quintile of total FM, central FM, peripheral FM and
visceral fat level and to be sarcopenic. The relationships remained significant for total FM (RR = 2.16, 95 % CI 1.29–3.63),
central FM (RR = 1.85, 95 % CI 1.09–3.14), peripheral FM (RR = 2.67, 95 % CI 1.59–4.48), visceral fat level (RR = 2.28, 95 %
CI 1.32–3.94), BMI (RR = 2.25, 95 % CI 1.36–3.72) and waist circumference (RR = 1.63, 95 % CI 1.05–2.55) after
adjustments for alcohol, smoking, social class, physical activity and history of cardiovascular diseases or diabetes. After
further adjustments for interleukin-6 and insulin resistance, central FM, waist circumference and sarcopenia were no
longer significantly associated with SCI.
Conclusions: Increased levels of peripheral FM, visceral fat level, and BMI are associated with SCI among older people.
Distinct pathophysiological mechanisms link regional adipose tissue deposition and cognitive functioning.
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Background
Increased prevalence rates of severe cognitive impairment
and dementia are a worldwide health concern because
they have been associated with increased mortality rates
and posit a global financial burden [1]. Current global esti-
mates suggest that over 35 million people are affected by
dementia; with population ageing, the number of suf-
ferers worldwide is expected to increase dramatically by
2050 [1]. Prevalence estimates of mild cognitive impair-
ment (MCI) were shown to range between 2 % to 56 %
[2]. Among British men alone, prevalence rates of de-
mentia as high as 14.6 % for those aged 80–84 years
were reported in a recent study [3].
Current recommendations suggest that up to one third
of dementia cases may be preventable with attention to
modifiable risk factors [4]. One of the most consistently
proposed risk factors for mid-and late-life cognitive im-
pairment is obesity [4]. In studies assessing the relation-
ship between obesity and cognitive impairment, obesity
is commonly measured as body mass index (BMI), waist
circumference (WC) or waist-hip ratio (WHR) [5–11].
These proxies of adiposity, particularly BMI, have been
criticised as being indices of excess weight rather than
body fat or adiposity [12], thus obscuring the underlying
role of adipose tissue in cognitive impairment. Other
studies have therefore used refined adiposity measures
of body composition assessed by means of bioelectrical
impedance vector analysis (BIA) or dual energy x-ray ab-
sorptiometry (DEXA); the body composition measures
most commonly assessed using these techniques were
fat mass (FM) and fat-free mass [10, 13–15]. Complete
consensus concerning the associations between these
adiposity measures and cognitive impairment has not
been reached. Specifically some studies have shown a
significant positive association between loss of lean mass
[11, 16] or increases in FM [16] with impaired cognitive
functioning, while a lack of significant associations be-
tween these measures has also been documented [11, 14].
Regional deposition of adipose tissue has also been exam-
ined in relation to cognitive impairment [13, 15, 17, 18].
Computed tomography (CT)- assessed visceral and ab-
dominal fat were found to be significantly associated with
cognitive impairment [17, 18].
The relationship between sarcopenia and cognitive im-
pairment has also been characterised by conflicting evi-
dence. The term sarcopenia was originally used to
describe declines in skeletal muscle mass [19], and was
shown to be significantly associated with cognitive im-
pairment [10]. More recently, measures of muscle func-
tion were added to the operational definitions of
sarcopenia [20, 21]. A recent study by Hsu et al. [22]
used the definition of The European Working Group on
Sarcopenia in Older People (EWGSOP) [20], to define
sarcopenia using impaired grip strength and/or walking
speed in addition to muscle mass loss [22] and reported
positive associations between sarcopenia and cognitive
impairment. However, these findings are challenged by
findings from the Epidemiologie de l’Osteoporose (EPI-
DOS) cohort which suggest that sarcopenia is not asso-
ciated with cognitive impairment when adjusting for
potential confounders [23]. Specifically, van Kan et al.
[14] compared multiple definitions of sarcopenia, includ-
ing a) using only muscle mass measurements; b) defini-
tions of sarcopenia which take into account grip
strength in addition to muscle mass loss; and c) the
EWGSOP definition of sarcopenia. The results suggest
that regardless of the definition employed, sarcopenia is
not significantly associated with cognitive impairment
after adjustments for age, education, disability, physical
activity and recruitment centres [23]. More recently, the
Foundation for the National Institutes of Health (FNIH)
Sarcopenia Project introduced novel criteria for sarcope-
nia [21]. The potential advantages of the FNIH sarcope-
nia criteria are a) the two functional components of
sarcopenia, i.e. muscle mass and muscle strength, are
separate, consistent with the definition of severe sarco-
penia according to EWGSOP criteria [20]; and b) low
cut-offs for grip strength and muscle mass are used,
hence they are less inclusive and can therefore become
clinically more relevant [24]. Sarcopenia rates using
the definition proposed by the FNIH are yet to be ex-
amined in relation to cognitive functioning in the
older population.
Due to the inconsistent findings of previous research,
in this study we aimed to examine the associations of
anthropometric characteristics, regional and total body
composition measures assessed using BIA, and func-
tional sarcopenia using both the EWGSOP and FNIH
definitions, with cognitive impairment in a large repre-
sentative sample of the older British men. We hypothe-
sized that total and regional deposits of FM,
anthropometric characteristics as well as FNIH-defined
sarcopenia will be significantly associated with mild and
more severe cognitive impairment.
Methods
Study population
Study participants were members of the British Regional
Heart Study (BRHS), a study comprising a socially and
geographically representative sample of 7735 men aged
40–59 between 1978 and 1980 [25]. Participants were re-
cruited from general practices in 24 towns representative
of all major British regions. In 2010–12, 1,570 surviving
men were assessed with the Test Your Memory (TYM)
during the 30-year re-examination, which was attended by
1722 BRHS participants (55 % response rate). Study mem-
bers with complete data on the TYM were on average two
years younger (M= 78.25, SD = 4.55) in comparison to the
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remaining ones attending the physical examination
(M = 80.2, SD = 4.55; p < 0.01), however they did not
differ with respect to their social class (p = 0.38), edu-
cation (p = 0.29), alcohol consumption (p = 0.46),
mean BMI (p = 0.11) or smoking status (p = 0.84).
Ethical approval was provided by the National Re-
search Ethics Service (NRES) Committee for London.
All men provided written informed consent to the in-
vestigations, which were carried out in accordance
with the Declaration of Helsinki.
Outcome measure- cognitive function
Cognitive function was assessed using the TYM [26], a
simple 10-task self-assessment cognitive screening in-
strument which has sound psychometric properties
[26, 27], remarkable cross-cultural validity [28–30],
and good concurrent validity with established tests
[26, 31, 32]. Participants were classified in normal
cognitive ageing (NCA), mild cognitive impairment
(MCI) or severe cognitive impairment (SCI) groups.
Total scores below 33 and scores between 33 and 45
(if older than 80 years of age) or 46 (if younger than
80 years of age) were considered to be indicative of
SCI and MCI, respectively, consistent with the scores
reported in the original study on TYM by Brown
et al. (2009) for patients with Alzheimer’s disease and
healthy controls [26], and with the scoring sheet for
the TYM available by the Royal College of Psychia-
trists [33].
Anthropometric and body composition charateristics
The anthropometric characteristics considered for this
study included WC, WHR, BMI and mid-arm muscle
circumference (MAMC). Waist and hip circumference
(cm) was measured in duplicate with an insertion
tape (CMS Ltd London). Hip circumference was mea-
sured at the point of maximum circumference over
the buttocks. WC was measured from the midpoint
between the iliac crest and the lower ribs measured
at the sides. WHR was calculated as WC/(hip circumfer-
ence). BMI was calculated as weight/(height)2 (kg/m2).
MAMC was calculated as (mid-upper arm circumference)
− 0.3142 × (triceps skinfold thickness) [34].
BIA-assessed body composition characteristics were
obtained using the TANITA MA-418-BC impedance
analyser (Tanita Inc., Tokyo, Japan). The TANITA ana-
lyser calculates body fat based on the voltage drop from
foot to foot after a small alternating current is applied
through contact with two metal foot plates [35]. Assess-
ments included FM (kg), peripheral FM (kg), central FM
(kg), visceral fat level (FL) and predicted muscle mass
(MM) (kg). Peripheral FM and appendicular MM were
defined as the sum of the FM or MM of all four limbs,
respectively. Central FM was defined as trunk FM.
Visceral FL was based on abdominal BIA [36]. It ranged
from 1 to 59 with higher values indicating greater levels
of visceral fat. Body composition assessmentes were ad-
justed for height (m), by dividing by height-squared. BIA
has been shown to be influenced by the variability in fat-
free mass (FFM) hydration [37, 38], however studies in
selected populations have shown that BIA assessments
are comparable to the ones obtained by DXA [39, 40]
and that it is one of the most simple and efficient ways
to obtain body-composition characteristics, particularly
in cohort samples where cost-effectiveness is a major
issue due to the restricted amount of resources available
[41]. The EWGSOP has also approved BIA measure-
ments as a portable alternative to dual-energy X-ray ab-
sorptiometry [20].
Muscle function and sarcopenia
Gait speed was assessed by means of a walking test (time
taken, in seconds, to walk 3 m at normal walking pace).
Grip strength (in kilograms) was measured with a Jamar
Hydraulic Hand Dynamometer. Three measurements
were taken for each hand, and the best of six readings
was used for the analysis.
Two definitions of sarcopenia were used. The first de-
rived from the EWGSOP definition for severe sarcopenia
and included concurrent presence of low lean mass
(height-adjusted appendicular muscle mass < =7.23), low
grip strength (<30 kg) and low gait speed (<=0.8 m/s)
[20]. The second was developed by the FNIH sarcopenia
project and included BMI-adjusted low lean mass
(<0.789), low grip strenth (grip strength < 26 kg) and
slowness (gait speed < =0.8 m/s) [42].
Covariates
Insulin-resistance (IR) was assessed using the Homeosta-
sis Model Assessment (HOMA) as the product of fasting
glucose (mmol/l) and insulin (μU/ml) divided by the
constant 22.5 [43]. Inflammation was assessed using two
markers, interleukin-6 (IL-6) (pg/mL) and C-reactive
protein (CRP) (mg/L). History of cardiovascular diseases
(CVD) or diabetes was based on self-report of a doctor
diagnosis of coronary thrombosis, myocardial infarction,
stroke or diabetes. Socioeconomic position was defined
based on the longest-held occupation of subjects at
study entry (aged 40–59 years) in accordance to the
Registrar Generals’ Social Class Classification and has
been described elsewhere [44]. Education was measured
using information asked in a questionnaire in 1996 on
the age study members left their full-time education and
were classified into three categories using < =14 and <
=18 years as the cut-offs. Physical activity assessments
included walking, cycling and other sporting activities.
Physical activity scores were assigned on the basis of fre-
quency and type of activity and the men were divided
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into 6 groups: none, occasional, light, moderate,
moderately-vigorous and vigorous. Subjects were also
asked detailed questions about their smoking status and
alcohol consumption habits. Men were classified in four
groups according to their smoking habits as current
smokers, long term ex-smokers (gave up smoking before
1983), recent ex-smokers and those who never smoked.
Alcohol consumption was recorded using questions on
the frequency, quantity and type. Heavy drinking was de-
fined as drinking more than six units (1 UK unit = 10 g)
of alcohol daily or on most days.
Statistical analysis
Age-adjusted multinomial logistic regressions were per-
formed to examine the associations between anthropo-
metric and body composition characteristics, muscle
function, sarcopenia rates and muscle function with
TYM-defined cognitive functioning categories. In all
models, the NCA group was used as the reference
group. Next, age-adjusted multinomial logistic regres-
sions were performed to examine the relationship be-
tween upper tertiles of IR, IL-6 and CRP with cognitive
functioning groups. These models were then further ad-
justed for alcohol consumption, physical activity, social
class, smoking and history of CVD and diabetes. Age-
adjusted partial correlations were also computed to
examine the relationships between anthropometric and
body composition characteristics with IR and the inflam-
matory markers. After the examination of these relation-
ships, we performed further multinomial logistic
regressions to assess the associations between those an-
thropometric and body composition characteristics that
were significantly associated with cognitive group mem-
bership in the age-adjusted regression models, upon fur-
ther adjustments for IR, CRP or IL-6, alcohol
consumption, physical activity, social class, smoking and
history of CVD and diabetes. IR, CRP and IL-6 were nat-
ural log-transformed to account for their skewed distri-
bution and were entered in the models as continuous
variables. The remaining covariates were entered as cat-
egorical variables in the respective models. All analyses
were carried out using Stata/IC 13.1 (StataCorp LP,
College Station, TX, USA).
Results
Table 1 summarizes the baseline demographic and life-
style characteristic of the sample. Among 1,570 men in
the study, 801 (51 %) were classified in the NCA, 636
(41 %) in the MCI and 133 (8 %) in the SCI group. Mean
age and the proportion (%) of study members reporting
moderate to heavy alcohol consumption did not differ
between groups, however significantly higher rates of
participants with severe cognitive impairments were in a
manual social class, left their full-time education when
aged < = 14 years, reported being physical inactive and
having been smokers (p values < =0.001).
Table 2 summarizes the age-adjusted relative risk ra-
tios (RR) of the anthropometric characteristics and the
BIA-assessed body composition measures with the
TYM-defined cognitive functioning groups. With respect
to the anthropometric characteristics, in comparison to
participants in the NCA category those classified as hav-
ing SCI were significantly more likely to have WC >
102 cm (RR = 1.98, 95 % CI 1.36–2.87), BMI > 30 kg/m2
(RR = 2.59, 95 % CI 1.72–3.91) and less likely to be in
the bottom quintile of MAMC (<=22.09 cm) (RR = 0.57,
95 % CI 0.34–0.97). Participants with SCI were also sig-
nificantly more likely to be in the upper quintile of cen-
tral FM (RR = 2.24, 95 % CI 1.45–3.47), peripheral FM
(RR = 2.93, 95 % CI 1.90–4.50), visceral FL (RR = 2.77,
95 % CI 1.76–4.36), and overall FM (RR = 2.62, 95 % CI
1.71–4.04) in comparison to the NCA group. Study
members classified in the MCI group were also signifi-
cantly more likely to be in the upper quintile of visceral
FM (RR = 1.45, 95 % CI 1.08–1.95) but did not differ
compared with those in the NCA group with respect to
any of the remaining anthropometric or body compos-
ition characteristics.
Table 1 Baseline characteristics of sample across cognitive function groups in a population-based study of 1570 older British men
aged 71–92 years in 2010-12
Normal cognitive ageing
(n = 801, 51 %)
Mild cognitive impairment
(n = 636, 41 %)
Severe cognitive impairments
(n = 133, 8 %)
P value*
Total TYM Score (M ± SD) 47.73 ± 1.49 41.21 ± 3.13 27.43 (5.33) <.001
Age (M ± SD) 78.09 ± 4.39 78.32 ± 4.69 78.88 ± 4.76 0.16
Manual social class, n(%) 272 (35 %) 334 (54 %) 100 (76 %) <.001
Education, n(%) left full-time education
at age 14 years or earlier
138 (18 %) 140 (25 %) 44 (39 %) <.001
Physical Activity, Inactive, n(%) 274 (36 %) 247 (42 %) 61 (50 %) 0.001
Smoking, Never smoked, n(%) 344 (43 %) 209 (33 %) 41 (31 %) <.001
Alcohol Consumption, Moderate/Heavy Drinker, n(%) 25 (2 %) 10 (2 %) 3 (2 %) 0.99
*p value of respective Chi-square or ANOVA test
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Table 3 presents the relationships between sarcopenia
rates and cognitive functioning. In total, 2.5 % (n = 34)
of study members were identified as sarcopenic using
the EWGSOP-definition of severe sarcopenia and 2.7 %
(n = 36) using the one proposed by the FNIH sarcopenia
project. Higher rates of participants classified as sarcope-
nic were observed among the group of participants with
SCI in comparison to those in the NCA group for both,
the EWGSOP (RR = 4.65, 95 % CI 1.78–12.19) and the
FNIH definition (RR = 2.90, 95 % CI 1.04–8.05).
Table 4 summarizes the relationships between the
three cognitive functioning groups with IR, IL-6 and
CRP levels. The results suggest that participants in the
upper tertile of IR (RR = 1.87, 95 % CI 1.25–2.80), IL-6
(RR = 2.03, 95 % CI 1.37–3.01), and CRP (RR = 1.55,
95 % CI 1.05–2.30) were significantly more likely to be
in the SCI group in comparison to the NCA group after
adjusting for age. Upon further adjustments for alcohol
consumption, social class, physical activity, smoking and
history of CVDs or diabetes, only the relationship be-
tween IL-6 and SCI retained its significance (RR = 1.90,
95 % CI 1.20–3.01) and therefore it was considered as a
covariate in subsequent regression models.
Table 5 presents the correlation coefficients for the re-
lationships between anthropometric and body compos-
ition characteristics with IR and the inflammatory
markers. With the exception of the relationship between
CRP and MAMC (r = .04, p = 0.11) all other age-adjusted
partial correlation coefficients were statistically signifi-
cant. These ranged from 0.12 (r = 0.12, p < 0.001) for the
relationship between MAMC and IR, to 0.48 for the re-
lationship between total FM and IR (r = 0.48, p < 0.001).
Results of age-adjusted logistic regression model showed
additionally that study members classified as having
Table 2 Relationships between obesity and regional adipose deposition with cognitive impairment in a study of British men aged
71–92 years in 2010–12
Normal cognitive
ageing (n = 801, 51 %)
Mild cognitive impairment
(n = 636, 41 %)
Severe cognitive
impairment (n = 133, 8 %)
P value*
Anthropometric characteristics
Waist Circumference
High Waist Circumference (>102 cm), n(%) 288 (36 %) 259 (41 %) 69 (52 %) .001
Relative Risk Ratio (95 % CI) 1.00 1.23 (1.00–1.53) 1.98 (1.36–2.87)‡
Waist-Hip Ratio
Top Quintile (> = 1.00), n(%) 151 (19 %) 126 (21 %) 27 (22 %) .75
Relative Risk Ratio (95 % CI) 1.00 1.09 (0.83–1.42) 1.19 (0.75–1.89)
MAMC
Bottom Quintile (<=22.09 cm), n(%) 169 (21 %) 125 (20 %) 19 (14 %) 0.20
Relative Risk Ratio (95 % CI) 1.00 0.89 (0.69–1.16) 0.57 (0.34–0.97)†
BMI
Obese (>30 kg/m2), n(%) 137 (17 %) 124 (20 %) 44 (34 %) <.001
Relative Risk Ratio (95 % CI) 1.00 1.19 (0.91–1.57) 2.59 (1.72–3.91)‡
BIA-assessed regional and total adiposity measures
Central FM
Top Quintile (> = 6.3 kg/m2), n(%) 135 (18 %) 112 (20 %) 37 (33 %) .001
Relative Risk Ratio (95 % CI) 1.00 1.12 (0.84–1.48) 2.24 (1.45–3.47)‡
Peripheral FM
Top Quintile (> = 3.4 kg/m2), n(%) 132 (18 %) 110 (19 %) 42 (38 %) <.001
Relative Risk Ratio (95 % CI) 1.00 1.13 (0.85–1.50) 2.93 (1.90–4.50)‡
Visceral fat level
Top Quintile (> = 6.9), n(%) 109 (16 %) 114 (22 %) 37 (35 %) <.001
Relative Risk Ratio (95 % CI) 1.00 1.45 (1.08–1.95)† 2.77 (1.76–4.36)‡
Total FM
Top Quintile (> = 9.7 kg/m2), n(%) 131 (18 %) 113 (20 %) 40 (35 %) <.001
Relative Risk Ratio (95 % CI) 1.00 1.18 (0.89–1.55) 2.62 (1.71–4.04)‡
MAMC Mid-arm muscle circumference, BMI Body-Mass Index, FM Fat Mass
*p-value of Chi-Square test
†p < .05
‡p < .01
risk ratios are age-adjusted
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sarcopenia using the FNIH definition were more likely
to be in the upper tertile of IR (odds ratio (OR) = 2.27,
95 % CI 1.10–4.68), CRP (OR = 3.03, 95 % CI 1.44–6.35)
and IL-6 (OR = 2.97, 95 % CI 1.39–6.32). Those classi-
fied as having sarcopenia using the EWGSOP definition
of severe sarcopenia did not differ significantly with re-
spect to any of the metabolic or inflammatory markers
in comparison to non-sarcopenic study participants.
As shown in Table 6, after further adjusting for alco-
hol, smoking, social class, physical activity, history of
CVD, and history of diabetes, study members with WC >
102 cm (RR = 1.63, 95 % CI 1.05–2.55), BMI > 30 kg/
m2(RR = 2.25, 95 % CI 1.36–3.72), those in the upper
quintile of central FM (RR = 1.85, 95 % CI 1.09–3.14), per-
ipheral FM (RR = 2.67, 95 % CI 1.59–4.48), visceral FM
(RR = 2.28, 95 % CI 1.32–3.94) and total FM (RR = 2.16,
95 % CI 1.29–3.63) were still more likely to be in the SCI
in comparison to the NCA group. With the exception of
central FM and WC these relationships remained signifi-
cant after adjustments for IL-6; additionally, being in the
upper quintile of overall FM or central FM, or having
WC> 102 cm, was no longer significantly associated with
membership in the SCI group (all p values > 0.05) after ad-
justments for IR. Finally, sarcopenia using either of the
two definitions employed was not significantly associated
with cognitive impairment after adjustments for alcohol,
smoking, social class, physical activity, history of CVD,
history of diabetes, IL-6 and IR. The results remained con-
sistent when adjusting for CRP as an additional measure
of inflammation and after substituting social class in the
regression models with education. The latter ones were
not controlled for in the same regression models because
they were highly correlated and would therefore result in
inflated estimates of the regression coefficients.
Discussion
The findings of this study suggest that cognitive func-
tioning is associated not only with conventional an-
thropometric measures of total adiposity, particularly
BMI and WC, but also with refined BIA-assessed mea-
sures of total and regionally deposited FM. The relation-
ships between BMI, peripheral FM, visceral FM and SCI
remained significant upon adjustments for lifestyle and
sociodemographic factors, as well as inflammatory and
metabolic markers. In contrast, central FM and WC did
not retain their significant associations with SCI upon
adjustments for IR or IL-6, suggesting unique patho-
physiological pathways linking regional FM deposition
and cognitive functioning. Higher rates of participants
with excess visceral FM were also identified among
people with MCI. Finally, although higher rates of indi-
viduals classified as sarcopenic using the EWGSOP and
Table 3 Relationships between EWGSOP and FNIH-defined sarcopenia with cognitive impairment in a study of British men aged
71–92 years in 2010-12
Normal cognitive
ageing (n = 801, 51 %)
Mild cognitive impairment
(n = 636, 41 %)
Severe cognitive impairment
(n = 133, 8 %)
P value*
Lean mass, grip strength and gait speed cut-offs
Appendicular Muscle Mass/BMI- FNIH cut-off
(<0.789), n(%)
119 (16 %) 131 (23 %) 35 (32 %) <.001
Relative Risk Ratio (95 % CI) 1.00 1.57 (1.19–2.09)‡ 2.39 (1.51–3.77)‡
Appendicular Muscle Mass/height- EWGSOP
cut-off (<=7.23), n(%)
185 (25 %) 137 (24 %) 31 (19 %) .37
Relative Risk Ratio (95 % CI) 1.00 0.95 (0.73–1.23) 0.65 (0.39–1.08)
Grip strength- FNIH cut-off (<26 kg), n(%) 190 (25 %) 169 (28 %) 38 (29 %) .30
Relative Risk Ratio (95 % CI) 1.00 1.16 (0.90–1.48) 1.20 (0.79–1.83)
Grip strength- EWGSOP cut-off (<30 kg), n(%) 257 (33 %) 234 (38 %) 57 (44 %) .02
Relative Risk Ratio (95 % CI) 1.00 1.23 (0.98–1.54) 1.48 (1.01–2.19)†
Gait Speed (<=0.8 m/s), n(%) 187 (24 %) 223 (36 %) 57 (45 %) <.001
Relative Risk Ratio (95 % CI) 1.00 1.83 (1.45–2.33)‡ 2.60 (1.74–3.87)‡
Sarcopenia
Severe Sarcopenia- EWGSOP definition, n(%) 11 (1.5 %) 15 (2.8 %) 8 (7.5 %) .001
Relative Risk Ratio (95 % CI) 1.00 1.78 (0.80–3.95) 4.65 (1.78–12.19)‡
Sarcopenia- FNIH definition, n(%) 13 (1.8 %) 17 (3.2 %) 6 (5.7 %) .04
Relative Risk Ratio (95 % CI) 1.00 1.70 (0.81–3.57) 2.90 (1.04–8.05)†
EWGSOP European Working Group on Sarcopenia in Older People, FNIH Foundation for the National Institutes of Health Sarcopenia Project
*p-value of respective Chi-Square test
†p < .05
‡p < .01
risk ratios are age-adjusted
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the FNIH definition were found among the SCI com-
pared to the NCA group, these relationships did not re-
tain their significance level after adjustments for relevant
covariates.
Comparison with other studies
The results of this study are comparable with the major-
ity of studies examining the relationships between com-
monly assessed markers of overall adiposity, such as
BMI or WC, with cognitive abilities which have reported
significant positive associations [10, 16, 45]. While a re-
cent large-scale study suggested that obesity acts as a
protective factor for dementia, the reasons of these asso-
ciations are unclear [46]. Moreover, in agreement with a
study using BIA-assessments of lean mass and FM [16],
our study identified significant associations between sev-
eral refined FM measures and cognitive dysfunctions.
However, while the effects of BMI and visceral fat
remained significant after adjustments for inflammatory
and metabolic markers, WC and central FM were not
significantly associated with SCI after adjustments for
inflammatory markers or IR. WC appears, therefore, to
be an index of central adiposity while BMI rather a
measure of excess weight rather than body fat, in agree-
ment with previous recommendations [47]. These find-
ings are also consistent with current evidence suggesting
that the negative effects of visceral adiposity on brain
volume is reduced yet persists after controlling for IR
[15], and that central adiposity plays a role in inflamma-
tory processes which appears to be independent of total
body FM [48].
In line with findings of a recent study on 731 elderly
subjects which did not identify a significant link between
sarcopenia and global cognitive functioning scores, but
rather just the verbal fluency cognitive domain [49], our
results suggest that sarcopenia is not significantly associ-
ated with cognitive functioning groups defined using
total TYM scores. Moreover, available evidence suggests
that impaired cognitive functions and EWGSOP-defined
sarcopenia are significantly associated [22], although
these relationships have been accounted for by con-
founding variables in a study by van Kan et al. [14, 23].
Our study confirms this finding and extends it using the
FNIH definition of sarcopenia, in addition to the EWG-
SOP definition of severe sarcopenia. While age-adjusted
regression models suggested that sarcopenia using is
Table 4 Relationships between insulin-resistance and inflammatory markers with cognitive impairment
Normal cognitive ageing
(n = 801, 51 %)
Mild cognitive impairment
(n = 636, 41 %)
Severe cognitive impairment
(n = 133, 8 %)
P value*
HOMA
Top Tertile (> = 2.63), n(%) 221 (32 %) 186 (33 %) 53 (46 %) .01
Relative Risk Ratio (95 % CI)a 1.00 1.05 (0.83–1.33) 1.87 (1.25–2.80)ǁ
Relative Risk Ratio (95 % CI)b 1.00 0.92 (0.69–1.22) 1.58 (0.97–2.58)
Interleukin-6
Top Tertile (> = 3.8 pg/L), n(%) 223 (30 %) 211 (35 %) 58 (48 %) <.001
Relative Risk Ratio (95 % CI)a 1.00 1.26 (1.00–1.59) 2.03 (1.37–3.01)ǁ
Relative Risk Ratio (95 % CI)b 1.00 1.03 (0.79–1.35) 1.90 (1.20–3.01)ǁ
C-Reactive Protein
Top Tertile (> = 2.2 mg/L), n(%) 234 (31 %) 202 (34 %) 52 (43 %) .05
Relative Risk Ratio (95 % CI)a 1.00 1.10 (0.88–1.39) 1.55 (1.05–2.30)§
Relative Risk Ratio (95 % CI)b 1.00 1.00 (0.77–1.30) 1.40 (0.89–2.21)
HOMA: Homeostasis Model Assessment for Insulin resistance
*p-value of respective Chi-square test
§p < .05
ǁp < .01
aModels adjusted for age
bModels adjusted for age, alcohol consumption, social class, physical activity, smoking, history of CVDs and diabetes
Table 5 Age-adjusted correlations between adiposity measures,
insulin resistance and inflammatory markers
Insulin
resistance
Interleukin-6 C-reactive
protein
Waist Circumference .45† .19† .23†
Waist-Hip Ratio .33† .17† .22†
MAMC .12† .12† .04
BMI .43† .18† .20†
Central Fat Mass .46† .19† .23†
Peripheral Fat Mass .47† .16† .22†
Visceral Fat Level .41† .18† .22†
Total Fat Mass .48† .18† .23†
All partial correlations are age-adjusted
MAMC Mid-arm muscle circumference, BMI Body-Mass Index
*p < .05
†p < .01
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more prevalent among people with SCI, these differences
were accounted for by alcohol consumption, smoking,
physical activity, history of CVD or diabetes and meta-
bolic and inflammatory markers. Interestingly, of the
three components comprising the definitions of sarcope-
nia, i.e. low lean mass, slowness and low grip strength,
the latter showed the strongest association with SCI.
This finding is likely to reflect a reverse causation bias
according to findings based on prospectively collected
data which suggest that cognitive decline precedes the
onset of muscle weakness [50]. The temporal relation-
ship between the newer definitions of sarcopenia and
cognitive impairment should therefore be replicated
using longitudinal data.
Suggested pathophysiological pathways linking adiposity
and cognitive functions
One suggested physiological pathway linking adipose tis-
sue deposition and severe cognitive impairment is through
alterations in IR [51, 52]. Specifically, adipocytes have a
metabolically active role on the central nervous system by
modulating biological pathways, including impairing insu-
lin sensitivity [53, 54]. Impaired brain insulin signalling
has been linked to AD [55], with increased IR being add-
itionally demonstrated to be associated with synaptic
failure, brain atrophy, and cognitive declines [55]. Further-
more, it has been shown that trunk FM is unfavorably as-
sociated with IR [56]. Since the results of this study show
that the relationships between central FM and WC were
no longer significant with AD range of cognitive function-
ing after controlling for IR, it is possible that the relation-
ship between central adipose tissue deposition and
cognitive functioning is, at least partially, mediated by IR.
The effects of peripheral FM pertained after adjusting for
IR and metabolic markers, suggesting a potentially more
complex pathophysiological mechanism linking peripheral
FM and cognitive impairment.
Another suggested pathway relating excess adipose tis-
sue deposition and cognitive impairment is via inflam-
matory processes. In our study, the associations between
SCI and WC or central FM were not significant after ad-
justments for IL-6 or CRP. Research suggests that cen-
tral adiposity plays a role in inflammatory processes
which appears to be independent of total body fat mass
[48], and the defective ability to maintain low inflamma-
tion levels contributes in its turn to the onset of AD
[57]. It is therefore possible that differing regional depo-
sitions of adipose tissue follow a different physiological
pathway to affect cognitive functions; however, these are
yet to be systematically tested, particularly in studies
making use of prospective data.
Strengths and limitations
We believe that this is the first study examining relative
adiposity measures, detailed measures of FM, and severe
sarcopenia defined using the EWGSOP and the FNIH
operational definitions in relation to both, mild and se-
vere cognitive impairment in a general-population
Table 6 Associations between adiposity measures, sarcopenia and cognitive function after adjustments for sociodemographic
characteristics, lifestyle factors and inflammatory or metabolic markers in a study of British men aged 71–92 years in 2010-12
Mild cognitive impairment (n = 636, 41 %) Severe cognitive impairment (n = 133, 8 %)
RR (95 % CI)a RR (95 % CI)b RR (95 % CI)c RR (95 % CI) a RR (95 % CI) b RR (95 % CI)c
Waist Circumference (>102 cm) 1.14 (0.88–1.46) 1.25 (0.95–1.66) 1.15 (0.88–1.49) 1.63 (1.05–2.55)§ 1.55 (0.94–2.55) 1.52 (0.95–2.43)
BMI (>30 kg/m2) 1.18 (0.86–1.62) 1.22 (0.85–1.75) 1.16 (0.83–1.62) 2.25 (1.36–3.72)ǁ 2.09 (1.17–3.72)§ 2.30 (1.36–3.91)ǁ
MAMC Bottom Quintile
(<=22.09 cm)
0.91 (0.67–1.23) 0.87 (0.63–1.20) 0.87 (0.64–1.19) 0.76 (0.42–1.36) 0.69 (0.37–1.31) 0.76 (0.42–1.40)
Central Fat Mass Top Quintile
(> = 6.3 kg/m2)
0.99 (0.71–1.37) 1.20 (0.83–1.74) 1.06 (0.75–1.49) 1.85 (1.09–3.14)§ 1.36 (0.72–2.59) 1.65 (0.93–2.91)
Peripheral Fat Mass Top Quintile
(> = 3.4 kg/m2)
1.00 (0.72–1.40) 1.16 (0.80–1.69) 1.06 (0.75–1.50) 2.67 (1.59–4.48)ǁ 2.25 (1.23–4.13)ǁ 2.57 (1.48–4.45)ǁ
Visceral Fat Level Top Quintile
(> = 6.9/m2)
1.33 (0.94–1.88) 1.54 (1.05–2.28)§ 1.35 (0.94–1.95) 2.28 (1.32–3.94)ǁ 1.99 (1.05–3.78)§ 2.27 (1.27–4.06)ǁ
Total Fat Mass Upper Quintile
(> = 9.7 kg/m2)
1.04 (0.75–1.44) 1.28 (0.88–1.85) 1.13 (0.80–1.59) 2.16 (1.29–3.63)ǁ 1.70 (0.92–3.15) 2.01 (1.16–3.49)§
Sarcopenia (Severe) - EWGSOP definition 1.31 (0.53–3.22) 1.41 (0.56–3.54) 1.40 (0.56–3.51) 2.79 (0.89–8.74) 2.67 (0.78–9.20) 2.84 (0.89–9.09)
Sarcopenia - FNIH definition 1.41 (0.58–3.39) 1.81 (0.71–4.64) 1.72 (0.67–4.40) 1.30 (0.32–5.18) 1.64 (0.39–6.91) 1.47 (0.35–6.12)
Reference is the normal cognitive ageing group
RR Relative risk ratios, MAMC Mid-arm muscle circumference, BMI Body-Mass Index, CVD Cardiovascular Disease, IR Insulin-resistance, IL-6 Interleukin-6, FNIH Foundation
for the National Institutes of Health, EWGSOP European Working Group on Sarcopenia in Older People
§p < .05
ǁp < .01
a Models adjusted for age, alcohol consumption, smoking, social class, physical activity, history of CVD, and history of diabetes
b Models adjusted for age, alcohol consumption, smoking, social class, physical activity, history of CVD, history of diabetes and IR
c Models adjusted for age, alcohol consumption, smoking, social class, physical activity, history of CVD, history of diabetes and IL-6
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sample of older people. The BRHS is a highly represen-
tative sample of the older male UK population which
has been successful in keeping attrition rates at very low
levels (98 % follow-up rate).
One of the limitation of this study relates to the self-
report nature of the TYM. However, we believe that it is
an accurate proxy of cognitive function because in clin-
ical settings it has shown good concurrent validity with
established tests [26, 31, 32]. We have also shown in a
recent study that the cardiometabolic and sociodemo-
graphic correlates of TYM-defined cognitive groups in
the BRHS are identical to those extracted using estab-
lished screening tools [58]. In addition, the proportion of
participants classified as being in the MCI or SCI range
of cognitive functioning using the TYM, is in line with
the prevalence rates reported in studies using different
diagnostic criteria [1, 2]. The available literature has
shown that the respective prevalence rates for mild
forms of cognitive dysfunction and Alzheimer’s Disease
range between 2 % to 56 % [2] and 2 % to 8.5 %, respect-
ively, for those aged 60 years and over [1].
However, the cross-sectional nature of this investigation
means that the direction of causation in the associations
observed cannot be directly inferred. To address this, we
performed exploratory analyses comparing BMI assess-
ments in our study population measured 10 years prior to
administration of the TYM. Results of these analyses
showed that participants classified in the SCI group had
significantly increased BMI 10 years prior to their cogni-
tive screening. It is, therefore, more likely that increased
obesity precedes cognitive impairment rather than vice
versa. The results presented in this study are also subject
to the sampling bias introduced by the 55 % overall re-
sponse rate of the BRHS. Nevertheless, study members
who were lost between the 20- and the 30-year re-
examination were more likely to have a higher waist cir-
cumference, insulin resistance and IL-6 levels compared
with those with complete data in both assessments; there-
fore, it is likely that the observed association between cog-
nitive impairment and waist circumference would be
more prominent if response rates were higher. In contrast,
mean BMI rates did not differ significantly between the
groups. Results relative to sarcopenia rates should be
interpreted with caution because these analyses were
somewhat underpowered given the low prevalence of sar-
copenia. In addition, 73 % of the sample attending the as-
sessment completed the TYM, which poses an additional
selection bias. Finally, the BRHS includes only white Euro-
pean men, therefore the generalisability of the findings to
women and other ethnic groups is limited.
Conclusions
The results of this study suggest that BMI, WC, as well
as BIA-assessed total FM, peripheral FM and central FM
are strongly associated with severe cognitive impairment.
Central FM and WC are no longer associated with SCI
after adjustuments for metabolic and inflammatory
markers suggesting that regional depositions of adipose
tissue might affect cognitive abilities through different
biological mechanisms. Therefore, specific regional adi-
pose tissue deposition patterns and not just the accumu-
lation of fat mass might be one of the missing links in
the attempts to understand the pathophysiological
mechanisms linking obesity and cognitive impairment.
Finally, sarcopenia, when defined using strict cut offs for
lean mass loss, gait speed and grip strenth is not associ-
ated with SCI; this relationship appears to be entirely
accounted for by age, alcohol consumption, smoking, so-
cial class, physical activity, history of CVD, history of
diabetes and inflammatory or metabolic markers.
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